- Home
- KALU vs DAWN Comparison
KALU vs DAWN Comparison
Compare KALU & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- DAWN
- Stock Information
- Founded
- KALU 1946
- DAWN 2018
- Country
- KALU United States
- DAWN United States
- Employees
- KALU N/A
- DAWN N/A
- Industry
- KALU Metal Fabrications
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- DAWN Health Care
- Exchange
- KALU Nasdaq
- DAWN Nasdaq
- Market Cap
- KALU 1.1B
- DAWN 1.2B
- IPO Year
- KALU 1991
- DAWN 2021
- Fundamental
- Price
- KALU $71.86
- DAWN $12.43
- Analyst Decision
- KALU Buy
- DAWN Strong Buy
- Analyst Count
- KALU 2
- DAWN 7
- Target Price
- KALU $90.00
- DAWN $36.17
- AVG Volume (30 Days)
- KALU 98.0K
- DAWN 782.5K
- Earning Date
- KALU 02-19-2025
- DAWN 02-25-2025
- Dividend Yield
- KALU 4.24%
- DAWN N/A
- EPS Growth
- KALU N/A
- DAWN N/A
- EPS
- KALU 2.87
- DAWN N/A
- Revenue
- KALU $3,024,000,000.00
- DAWN $101,953,000.00
- Revenue This Year
- KALU N/A
- DAWN N/A
- Revenue Next Year
- KALU $4.72
- DAWN $35.37
- P/E Ratio
- KALU $25.34
- DAWN N/A
- Revenue Growth
- KALU N/A
- DAWN N/A
- 52 Week Low
- KALU $63.44
- DAWN $11.13
- 52 Week High
- KALU $102.42
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- KALU 49.76
- DAWN 52.15
- Support Level
- KALU $69.59
- DAWN $11.65
- Resistance Level
- KALU $77.11
- DAWN $12.54
- Average True Range (ATR)
- KALU 2.40
- DAWN 0.47
- MACD
- KALU 0.27
- DAWN 0.02
- Stochastic Oscillator
- KALU 40.61
- DAWN 80.53
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.